# Natco Pharma Limited (NATCOPHARM)

> NATCOPHARM closed at ₹782.40 on 30 Oct 2026, trailing P/E 12.2, market cap ₹14,005 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Natco Pharma Limited (NSE: NATCOPHARM) closed at ₹782.40 on 30 Oct 2026, -5.3% over one year, against a 52-week range of ₹773.60 – ₹1,226.80.

In the quarter ended 30 Jun 2026 (consolidated, filed 14 Aug 2026) it reported revenue of ₹735 cr and net profit of ₹207 cr, a 28.1% net margin; revenue fell 44.7% and profit fell 67.5% year on year.

On four consecutive filed quarters its trailing P/E is 12.2; since 28 May 2025 its own P/E has ranged from 7.5 to 14.1 (median 9.7), and today's reading is higher than 75% of those 352 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 9.0%, ROCE 8.5%, debt-to-equity 0.08, Piotroski F-score 4 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 92% of 63 sector peers; PBT margin higher than 75% of 63 sector peers; ROE higher than 19% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹782.40 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -7.1% / -28.4% / -5.3% |
| 52-week low – high | ₹773.60 – ₹1,226.80 |
| Market capitalisation | ₹14,005 cr |
| Trailing P/E | 12.2 |
| Price / book | 1.52 |
| EV / EBITDA | 10.8 |
| Earnings yield | 8.2% |
| TTM EPS | ₹63.93 |
| TTM net profit | ₹1,144 cr |
| Quarter revenue | ₹735 cr |
| Quarter net profit | ₹207 cr |
| Net margin | 28.1% |
| Revenue growth (YoY) | -44.7% |
| Profit growth (YoY) | -67.5% |
| Return on equity | 9.0% |
| ROCE | 8.5% |
| Debt / equity | 0.08 |
| Current ratio | 3.01 |
| Free cash flow | ₹1,380 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹35.2 cr |

## Questions

### What is the P/E ratio of Natco Pharma Limited?

Natco Pharma Limited's trailing P/E is 12.2, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 28 May 2025 its P/E has ranged 7.5–14.1.

### What were Natco Pharma Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Natco Pharma Limited reported revenue of ₹735 cr and net profit of ₹207 cr (consolidated), filed with the exchange on 14 Aug 2026.

### What is Natco Pharma Limited's ROE?

Return on equity is 9.0% based on the balance sheet dated 31 Mar 2026.

### Does Natco Pharma Limited have debt?

Debt-to-equity is 0.08 on the balance sheet dated 31 Mar 2026.

### What is NATCOPHARM's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, NATCOPHARM traded between ₹773.60 and ₹1,226.80.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/NATCOPHARM

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._